120 Participants NeededMy employer runs this trial

Remote Electrical Neuromodulation for Migraine

Recruiting at 1 trial location
DH
YA
Overseen ByYara Asmar, BSc
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Theranica

What You Need to Know Before You Apply

What is the purpose of this trial?

Migraine and Fibromyalgia (FM) are chronic pain disorders characterized by altered central pain processing and impaired endogenous pain inhibition. FM presents with widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive symptoms and is strongly associated with central sensitization. Migraine similarly involves dysfunction of central inhibitory and descending pain modulation, with evidence of abnormal cortical excitability, impaired sensory habituation, and alterations in pain-related evoked potentials.

Conditioned Pain Modulation (CPM) is a measure of the body's endogenous pain-inhibitory mechanism, based on the phenomenon whereby the pain evoked by one painful stimulus (the test stimulus) is reduced by the concurrent application of a second, remote nociceptive stimulus (the conditioning stimulus). It is widely regarded as a proxy for the function of descending pain-modulatory pathways.

CPM is used as an experimental biomarker of descending pain inhibition across chronic pain conditions, including fibromyalgia and migraine. Studies consistently demonstrate reduced inhibitory responses in both migraine and fibromyalgia compared with healthy controls, indicating a robust deficit in descending pain modulatory systems. Combining a contact heat test stimulus (TS) with a cold pressor conditioning stimulus (CS) is a widely used and validated CPM paradigm.

Nerivio, a Remote Electrical Neuromodulation (REN) device, is a non-invasive, non-pharmacological therapy indicated for the acute and preventive treatment of migraine. The REN device is worn on the upper arm and delivers peripheral electrical stimulation to activate CPM-related descending inhibitory pathways and reduce migraine pain. This distal stimulation approach is designed to activate CPM-related circuits by recruiting brainstem pain-regulatory centers and modulating central nociceptive processing.

This randomized, double-blind, placebo-controlled trial is designed to assess the effect of a single REN session on CPM and cortical pain processing in adults with migraine or fibromyalgia. Using a standardized CPM induction protocol, the study will evaluate changes in behavioral CPM responses, before, during, and after REN vs. sham stimulation in patients with migraine or fibromyalgia. This study aims to clarify whether REN enhances descending pain inhibition and pain processing in populations with impaired endogenous pain modulation.

Who Is on the Research Team?

AS

Alit Stark Inbar, PhD

Principal Investigator

Theranica

Are You a Good Fit for This Trial?

This trial is for adults diagnosed with migraine or fibromyalgia. Participants should not have other major health issues that could interfere with the study, and must be able to use a wearable device on their upper arm.

Inclusion Criteria

Naïve to the Nerivio device
Must be able and willing to comply with the protocol
Provides written informed consent form
See 7 more

Exclusion Criteria

Has an implanted electrical and/or neurostimulation device (e.g., cardiac pacemaker, defibrillator, vagus nerve neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, cochlear implant, sphenopalatine ganglion stimulator, bladder stimulator, or occipital nerve stimulator)
Patients with severe depression
Pregnant or breastfeeding
See 4 more

What Are the Treatments Tested in This Trial?

Interventions

  • Remote Electrical Neuromodulation (REN) device

Trial Overview

The study tests a wearable device called Remote Electrical Neuromodulation (REN), which delivers mild electrical stimulation to the upper arm, against a placebo device. It aims to see if REN can improve how the body naturally reduces pain in people with migraine or fibromyalgia.

How Is the Trial Designed?

2

Treatment groups

Active Control

Placebo Group

Group I: Active REN treatmentActive Control1 Intervention
Group II: Placebo REN treatmentPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Theranica

Lead Sponsor

Trials
21
Recruited
41,700+